## **LETTER TO THE EDITOR**

## Comments on a Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia

Srinivasan Parthasarathy

Received on: 09 August 2022; Accepted on: 15 January 2023; Published on: 11 May 2023

**Keywords:** Eclampsia, Pregnancy induced hypertension, Premonitory symptoms. *Journal of South Asian Federation of Obstetrics and Gynaecology* (2023): 10.5005/jp-journals-10006-2216

## Dear Editor,

I read with interest the article on the role of Levetiracetam in the prevention of eclampsia. I have a few clarifications with regard to the article titled "A Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia". 1

The outcome measure and the necessity to remain the same or increase in the method of calculating sample size is unclear. The incidence of eclampsia in a case of severe preeclampsia is only 2–3% according to textbooks. Therefore, this problem is likely to escape and may prove to be inconsequential with the study sample of a total of 60. In such sample size studies, the authors could have used control to find out the real use. The authors have mentioned that there is a significant difference between the blood pressures of both groups on admission. This will lead to misinterpretation of results. There is a mention in Table 5 that the systolic blood pressure is 1133!!

What was the time duration between drug administration and delivery? Will it not change neonatal outcomes?

There are a lot of published studies on these issues.<sup>2,3</sup>

I request the authors to clarify on these issues for the benefit of readers.

## REFERENCES

1. Yaliwal RG, Biradar AM, Bhagavati SB, et al. A Randomized parallel noninferiority trial to evaluate the safety and efficacy of levetiracetam Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India

Corresponding Author: Srinivasan Parthasarathy, Department of Anaesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India, Phone: +91 9443142582, e-mail: painfreepartha@gmail.com

How to cite this article: Parthasarathy S. Comments on a Randomized Parallel Non-inferiority Trial to Evaluate the Safety and Efficacy of Levetiracetam in Comparison to Magnesium Sulfate in the Management of Severe Preeclampsia. J South Asian Feder Obst Gynae 2023;15(2):265.

Source of support: Nil
Conflict of interest: None

- in comparison to magnesium sulfate in the management of severe preeclampsia. J South Asian Feder Obst Gynae 2022;14(3):287–291. DOI: 10.5005/jp-journals-10006-2046.
- Anshu, Deepika. Maternal and perinatal outcome in severe pre-eclampsia and eclampsia. J South Asian Feder Obs Gynae 2009;1(3):25–28. DOI: 10.5005/jp-journals-10006-1005.
- Vaishnav SB, Raithatha N, Kathawadia K, et al. Making magnesium sulfate therapy safer in eclampsia: A comparative study of zuspan regime vs low-dose intravenous MgSO4 regime. J South Asian Feder Obst Gynae 2019;11(2):126–130. DOI: https://doi.org/10.5005/ jp-journals-10006-1675.

<sup>©</sup> The Author(s). 2023 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.